Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors
To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vi...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research Jg. 15; H. 9; S. 3177 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.05.2009
|
| Schlagworte: | |
| ISSN: | 1078-0432 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro.
In this phase I, open-label study, patients with advanced solid malignancies were treated with escalating doses of MG98 administered as a continuous i.v. infusion over 7 days repeated every 14 days. Cohorts of three patients, which could be expanded to six patients, were studied. The maximum tolerated dose was defined as the highest dose at which no more than 33% of subjects experienced dose-limiting toxicity. Pharmacokinetic and pharmacodynamic parameters of MG98 were also characterized.
Thirty-three patients were treated at doses of 100 to 250 mg/m(2)/d MG98. MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m(2)/d. One patient achieved a partial response and another prolonged disease stabilization. Plasma half-life of MG98 was short (2 hours), drug concentrations reaching a dose-dependent steady state during infusion with a volume of distribution equivalent to plasma volume. Suppression of DNMT1 expression was observed in 26 of 32 patients studied.
MG98 was well tolerated with early evidence of clinical activity. Proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development. |
|---|---|
| AbstractList | To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro.
In this phase I, open-label study, patients with advanced solid malignancies were treated with escalating doses of MG98 administered as a continuous i.v. infusion over 7 days repeated every 14 days. Cohorts of three patients, which could be expanded to six patients, were studied. The maximum tolerated dose was defined as the highest dose at which no more than 33% of subjects experienced dose-limiting toxicity. Pharmacokinetic and pharmacodynamic parameters of MG98 were also characterized.
Thirty-three patients were treated at doses of 100 to 250 mg/m(2)/d MG98. MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m(2)/d. One patient achieved a partial response and another prolonged disease stabilization. Plasma half-life of MG98 was short (2 hours), drug concentrations reaching a dose-dependent steady state during infusion with a volume of distribution equivalent to plasma volume. Suppression of DNMT1 expression was observed in 26 of 32 patients studied.
MG98 was well tolerated with early evidence of clinical activity. Proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development. To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro.PURPOSETo assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to DNA methyltransferase 1 (DNMT1), which has been shown to reduce CpG island methylation and allow reexpression of tumor suppressor genes in vitro.In this phase I, open-label study, patients with advanced solid malignancies were treated with escalating doses of MG98 administered as a continuous i.v. infusion over 7 days repeated every 14 days. Cohorts of three patients, which could be expanded to six patients, were studied. The maximum tolerated dose was defined as the highest dose at which no more than 33% of subjects experienced dose-limiting toxicity. Pharmacokinetic and pharmacodynamic parameters of MG98 were also characterized.EXPERIMENTAL DESIGNIn this phase I, open-label study, patients with advanced solid malignancies were treated with escalating doses of MG98 administered as a continuous i.v. infusion over 7 days repeated every 14 days. Cohorts of three patients, which could be expanded to six patients, were studied. The maximum tolerated dose was defined as the highest dose at which no more than 33% of subjects experienced dose-limiting toxicity. Pharmacokinetic and pharmacodynamic parameters of MG98 were also characterized.Thirty-three patients were treated at doses of 100 to 250 mg/m(2)/d MG98. MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m(2)/d. One patient achieved a partial response and another prolonged disease stabilization. Plasma half-life of MG98 was short (2 hours), drug concentrations reaching a dose-dependent steady state during infusion with a volume of distribution equivalent to plasma volume. Suppression of DNMT1 expression was observed in 26 of 32 patients studied.RESULTSThirty-three patients were treated at doses of 100 to 250 mg/m(2)/d MG98. MG98 was well tolerated with mild fatigue and myalgia, dose-limiting toxicity was asymptomatic transaminitis, and the maximum tolerated dose was 200 mg/m(2)/d. One patient achieved a partial response and another prolonged disease stabilization. Plasma half-life of MG98 was short (2 hours), drug concentrations reaching a dose-dependent steady state during infusion with a volume of distribution equivalent to plasma volume. Suppression of DNMT1 expression was observed in 26 of 32 patients studied.MG98 was well tolerated with early evidence of clinical activity. Proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development.CONCLUSIONSMG98 was well tolerated with early evidence of clinical activity. Proof of mechanism was observed and measurement of DNMT1 expression in peripheral blood mononuclear cells may be useful in future phase II development. |
| Author | Reid, Gregory K McLeod, A Robert Besterman, Jeffrey M de Bono, Johann Sludden, Julieann Coulthard, Sally Calvert, Hilary Siu, Lillian L Oza, Amit M Lee, Chooi Chen, Eric X Judson, Ian Boddy, Alan V Vidal, Laura Griffin, Melanie Lesley, Mark Plummer, Ruth |
| Author_xml | – sequence: 1 givenname: Ruth surname: Plummer fullname: Plummer, Ruth email: Ruth.plummer@ncl.ac.uk organization: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Ruth.plummer@ncl.ac.uk – sequence: 2 givenname: Laura surname: Vidal fullname: Vidal, Laura – sequence: 3 givenname: Melanie surname: Griffin fullname: Griffin, Melanie – sequence: 4 givenname: Mark surname: Lesley fullname: Lesley, Mark – sequence: 5 givenname: Johann surname: de Bono fullname: de Bono, Johann – sequence: 6 givenname: Sally surname: Coulthard fullname: Coulthard, Sally – sequence: 7 givenname: Julieann surname: Sludden fullname: Sludden, Julieann – sequence: 8 givenname: Lillian L surname: Siu fullname: Siu, Lillian L – sequence: 9 givenname: Eric X surname: Chen fullname: Chen, Eric X – sequence: 10 givenname: Amit M surname: Oza fullname: Oza, Amit M – sequence: 11 givenname: Gregory K surname: Reid fullname: Reid, Gregory K – sequence: 12 givenname: A Robert surname: McLeod fullname: McLeod, A Robert – sequence: 13 givenname: Jeffrey M surname: Besterman fullname: Besterman, Jeffrey M – sequence: 14 givenname: Chooi surname: Lee fullname: Lee, Chooi – sequence: 15 givenname: Ian surname: Judson fullname: Judson, Ian – sequence: 16 givenname: Hilary surname: Calvert fullname: Calvert, Hilary – sequence: 17 givenname: Alan V surname: Boddy fullname: Boddy, Alan V |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19383817$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kM1OwzAQhH0ooj_wCCCfODXFTuzEOVYFSiX-hOAcOfGmMUrsEjtFeRselVQUTrs7-mZG2ikaGWsAoQtKFpRycU1JIgLConCxWr0GRASh4OkITf71MZo690EIZZSwUzSmaSQiQZMJ-n6ppAO8wc53qse2xI_rVMyxNNjWemtNV9RgvVYwSF47MAOtTaVz7W174KuuGeCbpyVuwFd97VtpXAntIZbO8VbvwWDpsMRJoGQ_mMvOaWuGBe-k12C8w1_aV1iqvTQFKOyGaoV919jWnaGTUtYOzo9zht7vbt9W98HD83qzWj4EBaOJD0qqooLwWIUFU0VeMsWEGq48EXEec85DwmVI8ygVghAWqhTSlEFJZcIBYghn6Oo3d9fazw6czxrtCqhracB2LosTmoqIxwN4eQS7vAGV7VrdyLbP_n4a_gDetXts |
| CitedBy_id | crossref_primary_10_1038_s41392_019_0095_0 crossref_primary_10_1186_s13148_016_0264_8 crossref_primary_10_1517_17460441_2011_565744 crossref_primary_10_1111_epi_12031 crossref_primary_10_1007_s11523_017_0546_x crossref_primary_10_1007_s00296_021_04951_y crossref_primary_10_1016_j_cca_2019_10_021 crossref_primary_10_1200_JCO_2012_47_4957 crossref_primary_10_1016_j_urolonc_2012_03_015 crossref_primary_10_2165_11596690_000000000_00000 crossref_primary_10_1007_s13148_010_0007_1 crossref_primary_10_1371_journal_pone_0040024 crossref_primary_10_2217_epi_11_82 crossref_primary_10_2174_0929867325666180706105903 crossref_primary_10_2217_epi_15_83 crossref_primary_10_4155_fmc_09_105 crossref_primary_10_3389_fgene_2019_01125 crossref_primary_10_1016_j_cellsig_2011_02_003 crossref_primary_10_1016_j_fct_2018_10_052 crossref_primary_10_1007_s12035_013_8421_y crossref_primary_10_2217_epi_10_19 crossref_primary_10_1186_s13058_014_0441_7 crossref_primary_10_3389_fmolb_2022_976862 crossref_primary_10_1186_s40364_021_00280_1 crossref_primary_10_2217_epi_09_47 crossref_primary_10_1016_j_semcancer_2020_11_008 crossref_primary_10_1016_j_tips_2010_08_001 crossref_primary_10_1007_s13148_010_0011_5 crossref_primary_10_1007_s00705_023_05931_2 crossref_primary_10_3923_ijp_2011_294_315 crossref_primary_10_1042_BSR20211812 crossref_primary_10_1517_13543776_2012_729579 crossref_primary_10_1016_j_ejca_2017_05_006 crossref_primary_10_3389_fphar_2018_00366 crossref_primary_10_1111_febs_15750 crossref_primary_10_3390_ijms23168994 crossref_primary_10_3390_ijms241210130 crossref_primary_10_1038_s41698_025_01003_7 crossref_primary_10_1038_mtna_2012_19 crossref_primary_10_1097_DCR_0b013e318233a1ef crossref_primary_10_1016_j_bbcan_2021_188623 crossref_primary_10_1080_13543776_2016_1209488 crossref_primary_10_3390_cells10113064 crossref_primary_10_3390_ijms25126788 crossref_primary_10_3390_ijms241914964 crossref_primary_10_3390_biom7010003 crossref_primary_10_1155_2013_852080 crossref_primary_10_1097_CAD_0b013e32833a4352 crossref_primary_10_1016_j_biochi_2012_05_012 crossref_primary_10_3390_biomedicines11030654 crossref_primary_10_1089_rej_2012_1324 crossref_primary_10_1016_j_drup_2011_08_001 crossref_primary_10_1586_erm_12_39 crossref_primary_10_1007_s00432_022_04525_w crossref_primary_10_1016_j_ctrv_2017_01_004 crossref_primary_10_3390_cancers12041016 crossref_primary_10_1038_npp_2012_134 crossref_primary_10_1146_annurev_pharmtox_010617_053021 crossref_primary_10_1016_j_yrtph_2017_09_028 crossref_primary_10_3390_ph18050713 crossref_primary_10_1186_s12929_021_00721_x crossref_primary_10_1016_j_pharmthera_2015_04_001 crossref_primary_10_1186_s13148_021_01154_x crossref_primary_10_1038_s41392_024_01823_2 crossref_primary_10_1016_j_ab_2020_113823 crossref_primary_10_1002_wsbm_1206 crossref_primary_10_1016_j_molonc_2012_09_004 crossref_primary_10_2217_epi_2016_0150 crossref_primary_10_3390_cells9081850 crossref_primary_10_1016_j_pharmthera_2014_09_005 crossref_primary_10_1016_j_ajpath_2011_03_050 crossref_primary_10_3389_fgene_2014_00165 crossref_primary_10_1016_j_bbadis_2014_02_006 crossref_primary_10_1517_14656566_2016_1118053 crossref_primary_10_3390_ijms140715029 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-08-2859 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 19383817 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
| GroupedDBID | --- .55 18M 29B 2FS 2WC 34G 39C 3O- 4H- 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AFFNX AFHIN AFOSN AFRAH AFUMD AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 H~9 IH2 KQ8 L7B LSO MVM NPM OHT OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS VH1 VXZ W2D W8F WOQ X7M XJT YKV ZCG 7X8 AAFWJ AAJMC AETEA |
| ID | FETCH-LOGICAL-c417t-f1d3c056d2c4dcbf4d48d6d2b786b6555205a21b39880042d9e994ef1a75ee6e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 104 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000265712100029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-0432 |
| IngestDate | Sun Nov 09 11:25:15 EST 2025 Wed Feb 19 01:44:55 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c417t-f1d3c056d2c4dcbf4d48d6d2b786b6555205a21b39880042d9e994ef1a75ee6e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/15/9/3177/1988541/3177.pdf |
| PMID | 19383817 |
| PQID | 67198356 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_67198356 pubmed_primary_19383817 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-05-01 |
| PublicationDateYYYYMMDD | 2009-05-01 |
| PublicationDate_xml | – month: 05 year: 2009 text: 2009-05-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2009 |
| SSID | ssj0014104 |
| Score | 2.3029203 |
| Snippet | To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of MG98, an antisense oligonucleotide to... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3177 |
| SubjectTerms | Adult Aged Antineoplastic Agents - administration & dosage Cohort Studies DNA (Cytosine-5-)-Methyltransferase 1 DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors DNA (Cytosine-5-)-Methyltransferases - metabolism DNA Methylation Enzyme Inhibitors - administration & dosage Female Humans Infusions, Intravenous Male Maximum Tolerated Dose Middle Aged Neoplasm Staging Neoplasms - drug therapy Neoplasms - genetics Neoplasms - pathology Oligodeoxyribonucleotides - administration & dosage Oligodeoxyribonucleotides - pharmacokinetics Prognosis Thionucleotides - administration & dosage Thionucleotides - pharmacokinetics Tissue Distribution Treatment Outcome |
| Title | Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19383817 https://www.proquest.com/docview/67198356 |
| Volume | 15 |
| WOSCitedRecordID | wos000265712100029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEF7xqBAXWmiBUB5z4IgL63i9awkJRWlTkEgUVS3KLVp7x2Ap2CEPpPwbfiozjg2nqodeLHu1a1n7GM_ON_t9QpwyCZRD2pb4qCXDjNaLfQYcFQ1x7IIIS0mWu1vd65nBIOqviMv6LAynVdY2sTTUrkg4Rn4eatoeN1V4NX7yWDOKsdVKQGNVrDfJkeGELj14xxACWYoH0v7GeEw8V53fkcqcv5V9a7d_cYSQadz-7mOW_5rOx__7yk9iq_IxobWcFNtiBfMdsdGtUPTP4qX_QP8uuIGSWxaKFLo_I3MGNodilN0XOXMcF7PMIRWxWHNOtbP8IYtp-U-4fqnsB997LWAF6sVoVrq_OOHXyjO4ZxMKdgoWtOfsghqncw7L0Q1UTK5T4BAw1DkIQGsgczCbPxaT6Rfxp_Pjd_vaq5QavCSQeual0jUTcqWcnwQu4dy_wDh6irUJ41Ap5V8o68uYBsmwmXARRlGAqbRaIYbo74q1vMhxXwAG0hmmOcRmHFinIp-hPj_USWhDi6ohTuqeH9JKYHjD5ljMp8O67xtibzl4w_GSsGNITqphJsKDf7b9KjaXcBFnNB6K9ZRsAB6JD8kz9fbkuJxgdO31u69bJtoc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I+study+of+MG98%2C+an+oligonucleotide+antisense+inhibitor+of+human+DNA+methyltransferase+1%2C+given+as+a+7-day+infusion+in+patients+with+advanced+solid+tumors&rft.jtitle=Clinical+cancer+research&rft.au=Plummer%2C+Ruth&rft.au=Vidal%2C+Laura&rft.au=Griffin%2C+Melanie&rft.au=Lesley%2C+Mark&rft.date=2009-05-01&rft.issn=1078-0432&rft.volume=15&rft.issue=9&rft.spage=3177&rft_id=info:doi/10.1158%2F1078-0432.CCR-08-2859&rft_id=info%3Apmid%2F19383817&rft_id=info%3Apmid%2F19383817&rft.externalDocID=19383817 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |